Small molecules which reverse Chromium(iii) nicotinate treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00012075
TitleSmall molecules which reverse Chromium(iii) nicotinate treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Chromium(iii) nicotinate treatment in the subcutaneous fat tissues of type 2 Lepr(db/db) mice cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1d2e4e467bea600fb8dde
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatornbongio
CREEDS IDdrug:2590
Cell Typesubcutaneous fat tissues of type 2 Lepr(db/db) mice
Drug NameChromium(iii) nicotinate
Organismmouse
PubChem CID56843898
SMILES IDC1=CC(=CN=C1)C(=O)[O-].C1=CC(=CN=C1)C(=O)[O-].C1=CC(=CN=C1)C(=O)[O-].[Cr+3]
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM99687, GSM99688, GSM99689, GSM99690
Perturbed SamplesGSM99691, GSM99692, GSM99693, GSM99694
Tools used in the analysis
Dataset Accession
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
Datasets used in the analysis
Keyword
Tool Name
GSE4420
Gene Expression Omnibus
Niacin-bound chromium effect on the subcutaneous fat tissue of a model for type 2 diabetes with obesity
7
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.